$0.57
3.26% today
Nasdaq, Apr 04, 08:48 pm CET
ISIN
US8693671021
Symbol
STRO
Sector
Industry

Sutro Biopharma, Inc. Stock price

$0.59
-0.84 58.71% 1M
-2.94 83.22% 6M
-1.25 67.80% YTD
-4.50 88.36% 1Y
-8.24 93.29% 3Y
-8.81 93.70% 5Y
-14.61 96.10% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.04 6.01%
ISIN
US8693671021
Symbol
STRO
Sector
Industry

Key metrics

Market capitalization $49.64m
Enterprise Value $-63.30m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.33
EV/Sales (TTM) EV/Sales -1.02
P/S ratio (TTM) P/S ratio 0.80
P/B ratio (TTM) P/B ratio 1.10
Revenue growth (TTM) Revenue growth -59.64%
Revenue (TTM) Revenue $62.04m
EBIT (operating result TTM) EBIT $-238.45m
Free Cash Flow (TTM) Free Cash Flow $-194.64m
Cash position $316.90m
EPS (TTM) EPS $-3.01
P/E forward negative
P/S forward 1.05
EV/Sales forward negative
Short interest 5.58%
Show more

Is Sutro Biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Sutro Biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Sutro Biopharma, Inc. forecast:

4x Buy
36%
6x Hold
55%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Sutro Biopharma, Inc. forecast:

Buy
36%
Hold
55%
Sell
9%

Financial data from Sutro Biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
62 62
60% 60%
100%
- Direct Costs 7.22 7.22
11% 11%
12%
55 55
62% 62%
88%
- Selling and Administrative Expenses 34 34
27% 27%
55%
- Research and Development Expense 252 252
40% 40%
406%
-231 -231
185% 185%
-373%
- Depreciation and Amortization 7.22 7.22
11% 11%
12%
EBIT (Operating Income) EBIT -238 -238
167% 167%
-384%
Net Profit -227 -227
113% 113%
-367%

In millions USD.

Don't miss a Thing! We will send you all news about Sutro Biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sutro Biopharma, Inc. Stock News

Neutral
GlobeNewsWire
20 days ago
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - - The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater -
Neutral
GlobeNewsWire
22 days ago
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition –
Neutral
GlobeNewsWire
22 days ago
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner –
More Sutro Biopharma, Inc. News

Company Profile

Sutro Biopharma Inc. engages in the drug discovery, development, and manufacturing of pharmaceutical products. It focuses on next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jane Chung
Employees 338
Founded 2003
Website www.sutrobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today